EGFR and lung cancer: Our data suggest that the EGFR-L858R mutant promotes the expression of CXCR4 in lung cancer cells primarily through the ERK signaling pathway, rather than PI3K-AKT and JAK-STAT3 pathways (Fig. 4), thereby increasing invasive ability.